Skip to main content

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading "Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products"
Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  272.68
+1.51 (0.56%)
AAPL  293.32
+5.88 (2.05%)
AMD  455.19
+46.73 (11.44%)
BAC  51.31
-1.44 (-2.73%)
GOOG  397.05
+1.75 (0.44%)
META  609.63
-7.18 (-1.16%)
MSFT  415.12
-5.65 (-1.34%)
NVDA  215.20
+3.70 (1.75%)
ORCL  195.95
+1.36 (0.70%)
TSLA  428.35
+16.56 (4.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.